Health risks of radiation exposure in the moderate-to-high dose range have been well established. However, the risk remains unclear at low-dose ranges with protracted low-dose rate exposure, which is typical of occupational exposure. The purpose of this study is to construct a cohort of Korean radiation workers and to assess health effects associated with occupational radiation exposure. The study population is expected to be about 190,000 Korean radiation workers who have been registered with the Nuclear Safety and Security Commission since 1984. The national dose registry, the national cancer registry, the national vital statistics registry, and the national health insurance data are collected based on the Nuclear Safety Act. Through the linkage of those collected data, we will evaluate radiation-induced health risks including cancer and non-cancer diseases.

开始日期2021-11-18

申办/合作机构

Korea Institute of Radiological & Medical Sciences

KCT0005595 / WithdrawnN/A

Impact of SELf-obtained Vaginal Sample(SOVAS) for Detection of HPV DNA in An Institutional Health Screening Program (SELP-I)

开始日期2020-11-09

申办/合作机构

Korea Institute of Radiological & Medical Sciences

100 项与 Korea Institute of Radiological & Medical Sciences 相关的临床结果

登录后查看更多信息

0 项与 Korea Institute of Radiological & Medical Sciences 相关的专利（医药）

登录后查看更多信息

1,813

项与 Korea Institute of Radiological & Medical Sciences 相关的文献（医药）

2024-11-01·EUROPEAN JOURNAL OF PHARMACOLOGY

Anti-inflammatory effects of Gingerenone A through modulation of toll-like receptor signaling pathways

Article

作者: Youn, Hyung-Sun ; Gu, Gyo Jeong ; Ko, Hanbin ; Lee, Younghyun ; Kim, Byoung Soo ; Choi, Tae Hyun ; Lee, Ye Eun

Toll-like receptors (TLRs) play a pivotal role in initiating immune responses, particularly in the context of inflammation. However, an excessive inflammation can detrimentally affect the immune homeostasis Thus, it is important to regulate TLR signaling pathways appropriately. Gingerenone A (GIA), a bioactive compound derived from ginger, has garnered significant attention due to its potential anti-inflammatory properties. In this study, we investigate modulatory effects of GIA on TLR signaling pathways. Results showed that GIA effectively suppressed TLR-mediated inflammatory responses by modulating key signaling molecules such as nuclear factor kappa B and interferon regulatory factor 3. These results indicate that GIA is a novel regulator of TLR signaling, offering promising avenues for the development of new anti-inflammatory agents.

2024-10-15·Cancer research and treatment

Prognostic Significance of Bulky Nodal Disease in Anal Cancer Management: A Multi-institutional Study

Article

作者: Kim, Byoung Hyuck ; Chie, Eui Kyu ; Kang, Hyun-Cheol ; Kim, Eunji ; Kim, Mi-Sook ; Chun, Seok-Joo ; Jang, Won Il

Purpose This study aimed to assess the prognostic significance of bulky nodal involvement in patients with anal squamous cell carcinoma treated with definitive chemoradiotherapy.Materials and Methods We retrospectively analyzed medical records of patients diagnosed with anal squamous cell carcinoma who underwent definitive chemoradiotherapy at three medical centers between 2004 and 2021. Exclusion criteria included distant metastasis at diagnosis, 2D radiotherapy, and salvage treatment for local relapse. Bulky N+ was defined as nodes with a long diameter of 2 cm or greater.Results A total of 104 patients were included, comprising 51 with N0, 46 with non-bulky N+, and seven with bulky N+. The median follow-up duration was 54.0 months (range, 6.4 to 162.2 months). Estimated 5-year progression-free survival (PFS), loco-regional recurrence-free survival (LRRFS), and overall survival (OS) rates for patients with bulky N+ were 42.9%, 42.9%, and 47.6%, respectively. Bulky N+ was significantly associated with inferior PFS, LRRFS, and OS compared to patients without or with non-bulky N+, even after multivariate analysis. We proposed a new staging system incorporating bulky N+ as N2 category, with estimated 5-year LRRFS, PFS, and OS rates of 81.1%, 80.6%, and 86.2% for stage I, 67.7%, 60.9%, and 93.3% for stage II, and 42.9%, 42.9%, and 47.6% for stage III disease, enhancing the predictability of prognosis.Conclusion Patients with bulky nodal disease treated with standard chemoradiotherapy experienced poor survival outcomes, indicating the potential necessity for further treatment intensification.

2024-10-01·NUCLEAR MEDICINE COMMUNICATIONS

Evaluating 64Cu-DOTA-rituximab as a PET agent in patients with B-cell lymphoma: a head-to-head comparison with 18F-fluorodeoxyglucose PET/computed tomography

Article

作者: Kim, Byung Il ; Byun, Byung Hyun ; Kang, Chi Soo ; Lee, Inki ; Choi, Chang Woon ; Kang, Hye Jin ; Lee, Kyo Chul ; Kang, Joo Hyun ; Woo, Sang-Keun ; Lim, Ilhan

Background:

This study aimed to evaluate the biodistribution of 64Cu-DOTA-rituximab and its diagnostic feasibility for lymphoma using CD20-targeted 64Cu-DOTA-rituximab PET/computed tomography (PET/CT).

Methods:

A prospective study involving six patients diagnosed with lymphoma was conducted between January 2022 and January 2023. These patients underwent 18F-fluorodeoxyglucose (18F-FDG) and 64Cu-DOTA-rituximab PET/CT scans. 64Cu-DOTA-rituximab PET/CT images were acquired at 1, 24, and 48 h after administering 64Cu-DOTA-rituximab to assess the biodistribution and dosimetry over time. The observed lymph nodes were categorized into specific regions, including cervical and supraclavicular, axillary and infraclavicular, mediastinal, hilar, abdominal paraaortic and retroperitoneal, iliac, mesenteric, and inguinal regions, to compare the diagnostic ability of 18F-FDG and 64Cu-DOTA-rituximab PET/CT in detecting lymphoma lesions. Furthermore, the tumor-to-background ratio was calculated and compared with the maximum standardized uptake (SUVmax) of the tumors and the mean standardized uptake (SUVmean) of normal organs. Internal radiation dosimetry was determined using the OLINDA/EXM software.

Results:

64Cu-DOTA-rituximab uptake in lymph nodes associated with lymphoma progressively increased from 1 to 48 h after injection. In contrast, 64Cu-DOTA-rituximab uptake in normal organs, such as blood, lung, kidney, bladder, muscle, bone, and brain, decreased over time, whereas it increased in the liver and spleen. When it comes to the comparison between 64Cu-DOTA-rituximab and 18F-FDG, the SUVmax of tumors was higher on 64Cu-DOTA-rituximab PET/CT (18.1 ± 8.3) than on 18F-FDG PET/CT (5.2 ± 1.5). Additionally, the tumor-to-background ratio, measured using the SUVmean of normal muscles, was higher on 64Cu-DOTA-rituximab PET/CT (55.7 ± 31.0) than on 18F-FDG PET/CT (8.6 ± 2.8). No adverse events related to 64Cu-DOTA-rituximab injection were reported.

Conclusion:

The results of this study demonstrate the feasibility of using 64Cu-DOTA-rituximab PET/CT to evaluate the CD20 expression. The increased 64Cu-DOTA-rituximab uptake in lymph nodes associated with tumors, higher SUVmax, and tumor-to-muscle ratios observed with 64Cu-DOTA-rituximab PET/CT compared with 18F-FDG PET/CT, highlight the diagnostic potential of this imaging modality.

项与 Korea Institute of Radiological & Medical Sciences 相关的新闻（医药）

2022-10-12

·Healthcare IT News

5 South Korean hospitals to try out Deep Bio's AI support tool for prostate cancer diagnosis

South Korean medical AI developer Deep Bio is deploying its prostate cancer diagnosis support software to five local hospitals as part of a recently signed trial purchase agreement. The AI product will be tried out at SMG-SNU Boramae Medical Center, Chungnam National University Sejong Hospital, Korea Institute of Radiological & Medical Sciences, Jeju National University Hospital, and Gyeongsang National University Changwon Hospital. WHAT IT'S ABOUT The trial purchase comes ahead of the full integration of Deep Bio's DeepDx Prostate Pro into the hospitals' pathology workflows by November. It is intended to be used to support pathologists in tumour severity determination, confirmation of diagnoses, and research. The deep learning-based medical software analyses the whole slide image of prostate needle biopsies and automatically classifies the severity of prostate cancer. Based on evaluation studies, this tool showed 98.7% concordance in grade group classification and 96.9% concordance in "no grade" group classification compared with the reference standard created by three pathologists. THE LARGER TREND In November last year, Deep Bio received the approval of the Ministry of Food and Drug Safety for DeepDx Prostate Pro. In July this year, the software has been designated as an innovative product by South Korean regulators. The technology is currently being studied by researchers at the Stanford University School of Medicine, which recently extended its software license deal with the company. DeepDx Prostate is also being used by Morphle Labs' pathologists in India and the US. It is also being distributed around Switzerland and North Africa through Deep Bio's partnership with Swiss medical device distributor HealthCare Konnect. ON THE RECORD In a press statement, CEO Sun-Woo Kim said that "through this trial purchase project, Deep Bio will lead the introduction of digital pathology in Korea as well as accelerate domestic market expansion." "We are greatly expecting to prove that our software can be seamlessly integrated into the current pathology workflows, bringing positive changes such as reducing pathologists' work burden and improving efficiency in real clinical settings," he added.

合作

100 项与 Korea Institute of Radiological & Medical Sciences 相关的药物交易

登录后查看更多信息

100 项与 Korea Institute of Radiological & Medical Sciences 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

或

查看完整样例数据

管线布局

2024年11月22日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

药物发现

临床前

批准上市

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

Florapronol (18F) ( APP )	阿尔茨海默症更多	批准上市
AIU2008 ( FLT3 )	髓系白血病更多	临床前
2-脱氧-D-葡萄糖	肿瘤更多	临床前
TI3-D11 ( TNKS1 x TNKS2 )	结直肠癌更多	临床前
TI-61987 ( TNKS1 x TNKS2 )	结直肠癌更多	临床前